KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Free Cash Flow (2016 - 2025)

Merck (MRK) has disclosed Free Cash Flow for 17 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 27.42% to $1.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.4 billion through Dec 2025, down 31.7% year-over-year, with the annual reading at $12.4 billion for FY2025, 31.7% down from the prior year.
  • Free Cash Flow for Q4 2025 was $1.8 billion at Merck, down from $6.8 billion in the prior quarter.
  • The five-year high for Free Cash Flow was $8.5 billion in Q3 2024, with the low at -$743.0 million in Q4 2023.
  • Average Free Cash Flow over 5 years is $3.1 billion, with a median of $3.0 billion recorded in 2022.
  • The sharpest move saw Free Cash Flow surged 2290.51% in 2022, then plummeted 122.65% in 2023.
  • Over 5 years, Free Cash Flow stood at $3.9 billion in 2021, then decreased by 15.59% to $3.3 billion in 2022, then tumbled by 122.65% to -$743.0 million in 2023, then soared by 438.22% to $2.5 billion in 2024, then decreased by 27.42% to $1.8 billion in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $1.8 billion, $6.8 billion, and $2.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.